TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Also in this 12-page issue: ASCO urges freeze of Medicare payments for chemotherapy at 2004 levels for next two years. February 20, 2004
TCL Archive Questions Still Surround 88 BCDDP Patients Found With Minimal Cancer; DCCR Asks for Another Review October 28, 1977
